Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
HOME > BUSINESS
BUSINESS
- Takeda to Acquire US Dengue Vaccine Developer Inviragen
May 9, 2013
- Kowa to Initiate Domestic PI Clinical Study of Anticancer Drug Codeveloped by NanoCarrier
May 9, 2013
- IFRS Implications to Be Seen in In-Licensed Products, M&A Processing
May 9, 2013
- Maruishi Licenses New Kappa Opioid Agonist from Cara Therapeutics
May 8, 2013
- BMKK to Increase Number of MRs to 1,000 by 2015
May 8, 2013
- Astellas: FDA Advisory Panel Did Not Back Approval of Tivozanib
May 8, 2013
- Shionogi Sponsors EMPATHY Study to Build New Evidence for Statins
May 8, 2013
- AnGes MG Eyes PIII Trial for Collategene in US, Europe by 2013-End
May 8, 2013
- Nichi-Iko Voluntarily Recalls Enalapril Maleate Tablets
May 7, 2013
- BI Japan’s Ethical Drug Sales Up 7.3% with Prazaxa Sales of 23.5 Billion Yen
May 7, 2013
- Fujifilm Kyowa Kirin Biologics Looking for Marketing Partners in Europe and US: Executive VP Kawaguchi
May 7, 2013
- Mochida Files NDA for PAH Treatment Treprostinil
May 7, 2013
- Daiichi Sankyo, Perosphere to Develop Anticoagulant Reversal Agent for Edoxaban
May 2, 2013
- Anticancer Agent Xtandi Receives Positive Opinion for Marketing Approval by EMA: Astellas
May 2, 2013
- Boehringer to Enter Oncology Market, Hire 100 MRs in Japan
May 2, 2013
- Boehringer Chief Says Japan Business Successful
May 2, 2013
- Astellas Vice President Miyokawa to Be Promoted to Representative Director
May 2, 2013
- Novartis Investigating Employee Involvement in Retracted Diovan Papers
May 1, 2013
- Torii Aims for Sales of 63 Billion Yen in FY2015, Expanding Allergen Field
May 1, 2013
- Torii to Launch Anti-HIV Drug Stribild Combination Tablets on May 14
May 1, 2013
ページ
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…